Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.

Abhijit Datta Khoje,^a Aisvareya Kulendrn,^a Colin Charnock,^b Baojie Wan,^c Scott Franzblau,^c Lise-Lotte Gundersen^{a*}

(a) Department of Chemistry, University of Oslo, P.O. Box 1033, Blindern, N-0315 Oslo, Norway.

(b) Faculty of Health Sciences, Oslo University College, P.O. Box 4 St. Olavs plass, N-0130 Oslo, Norway.

(c) Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833S. Wood St., Chicago, Illinois 60612 USA.

Key Words: Tuberculosis; heterocycles; resistant strains

Abstract. Purine analogs modified in the 5-membered ring have been synthesized and examined for antibacterial activity against *Mycobacterium tuberculosis* $H_{37}Rv$ *in vitro* employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only found to be weak inhibitors, but the 8-aza-, 7-deaza- and 8-aza-7-deazapurine analogs studied displayed excellent antimycobacterial activities, some even substantially better than the parent purine. In the 7-deazapurine series, MIC values between 0.08 and 0.35 μ M, values comparable or better than the reference drugs used in the study (MIC rifampicin 0.09 μ M, MIC isoniazid 0.28 μ M and MIC PA-824 0.44 μ M). The five most active compounds were also examined against a panel of drug-resistant *Mtb* strain, and they all

^{*} to whom correspondence should be addressed. Tel.: +4722857019; Fax: +22855507; E-mail: 1.1.gundersen@kjemi.uio.no

retained their activity. The compounds examined were significantly less active against *M*. *tuberculosis* in a state of non-replicating persistence (NRP). MIC in the low-oxygen-recovery assay (LORA) $\geq 60 \ \mu$ M. The 7-deazapurines were somewhat more toxic towards mammalian cells, but still the selectivity indexes were excellent. The non-purine analogs exhibit a selective antimycobacterial activity. They were essentially inactive against *Staphylococcus aureus* and *Escherichia coli*.

Introduction

We have previously reported that certain 6,9-disubstituted purines are potent inhibitors of *Mycobacterium tuberculosis* (*Mtb*) *in vitro*.¹ These antimycobacterial purines display several properties which make them highly interesting as potential drugs against tuberculosis. These are high selectivity towards *Mtb* compared to other microorganisms, activity against several drug resistant strains of *Mtb*, generally low toxicity towards mammalian cells, and ability to affect *Mtb* inside macrophages. Figure 1 summarizes the current SAR knowledge as well as the structures of some of the most active compounds in this series.

(Fig. 1)

Tuberculosis (TB) still claims ca. 2 million deaths pr. year worldwide and resistance to existing drugs is a growing problem. Thus there is an urgent need for novel drugs for the treatment of TB. Agents that reduce the duration and complexity of the current therapy would have a major impact on the overall cure rate.² After exploring SAR of intact purines (Fig. 1), we now focus on non-purine analogs of compounds 1.³ Certain pyrimidine analogs (general structure **B**, Fig. 1) display activity comparable with the parent purine,^{3b,3d} but simple imidazole analogs (general structure **C**, Fig. 1) are only moderately active.^{3c} Herein we report the synthesis and antimycobacterial activities for purine analogs modified in the 5-membered ring (general structure **D**, Fig. 1).

Chemistry

The 8-azapurine **5** was readily available from the pyrimidine **2** as shown in Scheme 1. The synthesis of 7-deaza-8-azapurine **6** (Fig. 2) has been published by us before.^{3a}

(Scheme 1)

(Fig. 2)

In contrast with what has been reported for alkylation of the 7-deazapurine 7a,^{4,5} the benzylation shown in Scheme 2 went to completion at ambient temperature, and was reasonably regioselective. Compound **8a** was isolated in 81% and only minor amounts of more polar products (not isolated) were observed. Compound **8b** was prepared in high yield from the corresponding dichloro-7-deazapurine **7b**. Compounds **9a** – **d** were synthesized by Stille couplings on the chlorides **8**. Reactions on the dichloride **8b** were conducted at milder conditions in order to achieve complete regioselectivity. Finally the methoxy compound **9e** was formed by exchange of the chloride in compound **9c**. This is analogous with the previously reported synthesis of the 2-methoxypurine **1e** (Fig. 1).^{1f}

(Scheme 2)

9-Alkyl-9-deazapurines have been synthesized by time-consuming construction of the bicyclic ring system via pyrroles⁶ or pyrimidines,⁷ and alkyl- or acyl substituents have been introduced at C-9 in 6-oxo-9-deazapurines be Friedel-Craft alkylation or acylation, but the yields are generally quite modest.⁸ Instead, we evaluated several routes for the synthesis of our target 9-deazapurines **16** and **17** (Scheme 3), starting from 6-chloro-9-deazapurine (4-chloropyrrolo[3,2-*d*]pyrimidine) (**10**). The 4,7-dihalopyrrolo[3,2-*d*]pyrimidine **13a** were available be *N*-methylation and halogenation of compound **10**. Attempts to introduce the *p*-methoxybenzyl substituent at C-9 by Negishi couplings on the halide **13a** or the corresponding 7-iodo compound (not shown), met with little success. 9-Deazapurine can be lithiated at C-9 by metal-halogen exchange and the lithiated species may react with for instance imines^{7b,9} or amides.^{6c} However, attempts to introduce the desired C-9 substituent by lithiation of compound **13a** followed by reaction with *p*-methoxybenzyl halides failed. This was in part due to migration of lithium to C-8 before reaction with the alkyl halide. Also reactions between lithiated **13a** and anisaldehyde, the corresponding Weinreb amide, or benzoyl chloride turned out to be sluggish reactions. In our hands, the best route to the target molecule **17** is the one

shown in Scheme 3. Lithiated **13a** was trapped with DMF to give the aldehyde **14a** in a high yield. Compound **14a** was subsequently reacted with *p*-methoxyphenylmagnesium bromide. The secondary alcohol thus formed turned out to be difficult to isolate in pure form, but the adduct was instead subjected to *in situ* Oppenaur oxidation by benzaldehyde in the presence of LiCl^{10} to give the ketone **15a**. After introduction of the furyl group by a Stille coupling on the chloride **15a**, ketone **16a** was reduced to the target **17** under Wolff-Kishner conditions. Several other reduction methods were unsuccessful for this transformation.

Silyloxymethyl chlorides have been developed as reagents for N-¹¹ and O-protection,¹² and the protected compounds can be cleaved when treated with fluoride ions under milder conditions than normally required to cleave the analogous SEM-protected derivatives. The only commercially available of these reagents is (triisopropylsilyloxy)methyl chloride (TOM-Cl),¹³ and we chose the TOM group as N-protection group in the synthesis of target compound **16c**. The N-protected ketone **16b** was synthesized as described for compound **16a** above, and the protection group was conveniently removed by KF in methanol. The protection group was not compatible with the harsh conditions required in a Wolff-Kishner reduction, nor was the reduction of the carbonyl group compound **16c** successful. However, the 9-deazapurines **16a**, **16c** and **17** all turned out to be far less active as antimycobacterial compounds compared to the parent purine and the other non-purine analogs reported herein (see below), and no further attempts were made to synthesize an analog of compound **17** with a free NH-group.

(Scheme 3)

Biological evaluation

The target compounds 5, 6, 9a – 9e, 16a, 16c and 17 were screened for activity against *M*. *tuberculosis* H₃₇Rv (ATCC #27294) in the microplate alamar blue assay (MABA)¹⁴ and the MIC values are given in Table 1. The previously synthesized purines 1a and 1b were included for comparison. The substituents are defined in Fig. 1, and the detailed structures can be found in Fig. 2 and Schemes 1 - 3.

The deazapurines **16** and **17** were only weak inhibitors of antimycobacterial growth (MIC > 90 μ M). The low activities found discouraged us from synthesis of more compounds in this series as described above, and no further examination of antimycobacterial activities was done for these substances.

The 8-azapurine **5** and the 8-aza-7-deazapurine **6** were slightly less active than the parent purine **1a**, showing that the purine C-8 may be exchanged with a nitrogen without a significant loss of activity. However, the most intriguing results were found for the 7-deazapurines **9**. Compound **9a** was ca. 8 times more active than the parent purine **1a**. The thienyl derivative **9b** appeared to be a slightly weaker inhibitor than the furyl derivative **9a**. The same tendency has been observed in the purine series before.¹ In our study of the purines, we have generally seen that antimycobacterial activity is substantially increased when chlorine is introduced in the 2-position,¹ and compounds **9c** and **9d** were the among the most active in this series. The values were in the same range as for the drug rifampicin and better than for isoniazid or the promising drug candidate PA-824.¹⁵

In case of tuberculosis, a sub-population of the bacteria isolate in a state of non-replicating persistence (NRP). NRP is considered to be an important factor contributing to the long treatment duration (\geq 6 months required). Hence we wanted to investigate if the antimycobacterial purines and non-purine analogs described herein also could affect *Mtb* in NRP. Compounds **1a**, **1b**, **5**, **6** and **9a** – **9e** were thus tested in the low-oxygen-recovery assay (LORA)¹⁶ (Table 1). Unfortunately, as also seen for many known antituberculosis drugs¹⁶ including izoniazid, the compounds were not found to be very active in this assay. Interestingly, it seems likely that the thienyl substituent results in somewhat more active compounds, and that the chloride is not beneficial for activity in the LORA. The best inhibitor identified in this assay was the thienyl-7-deazapurine **9b** (MIC 60 μ M).

The antimycobacterial purine analogs 5, 6 and 9a - 9e were examined for toxicity against mammalian cells (VERO cells), and low EC₅₀ values were found (Table 1). All deazapurines 9 were more toxic towards VERO cells than compounds 1, 5 and 6, but the selectivity indexes (SI) were

still very good for these antimycobacterial compounds. For the best inhibitor of *Mtb* growth, compound **9c**, the SI was found to be > 1000.

The five most active deazapurines (9a - 9e) as well as the parent purine **1b** were examined against a panel of *Mtb* strains resistant to currently used anti-TB drugs; rifampicin (RMP), isoniazid (INH), streptomycin (SM), kanamycin (KM) and clofazimine (CLF) (Table 2). All compounds examined retained their activity against all the drug resistant strains applied in this study.

(Table 2)

In accordance with previous findings on the structurally related purines,¹ the non-purine analogs exhibit a selective antimycobacterial activity. Compounds **5**, **6**, **9a**, **9c**, **16a**, **16c** and **17** were tested against *Staphylococcus aureus* and *Escherichia coli* and were found to be essentially inactive (all MICs > 32 μ g/mL; >90 μ M). Even though the mode of action for our purines and non-purine analogs is not known, the lack of cross resistance and lack of actiity towards other bacteria points towards a novel mechanism of action and a target not found in all bacteria.

In summary, novel 8-aza-, 7-deaza- 9-deaza and 8-aza-7-deazapurines have been synthesized and their biological activities have been compared with those of known antimycobacterial purines with similar substitution patterns. It was found that the purine N-9 is important for activity, since the 9-deazapurines studied were only weak inhibitors of *Mtb* in the MABA. The purine C-8 may be exchanged with nitrogen without significant loss of activity and removal of the purine N-7 results in substantially improved growth inhibition. The best results were obtained for some of the 7-deazapurines with MIC in the MABA comparable with rifampicin. The compounds studied were generally of low toxicity towards mammalian (VERO) cells and essentially inactive against other bacteria (*S. aureus, E. coli*). Unfortunately, the compounds studied were not found to be very active against *Mtb* isolates in NRP.

Experimental

The ¹H NMR spectra were recorded at 500 MHz with a Bruker Avance DRX 500 instrument, at 300 MHz with a Bruker Avance DPX 300 instrument, or at 200 MHz with a Bruker Avance DPX 200

or a Varian Gemini instrument. The decoupled ¹³C NMR spectra were recorded at 125, 75 or 50 MHz using instruments mentioned above. Mass spectra under electron impact conditions were recorded with a VG Prospec instrument at 70 eV ionizing voltage, and are presented as m/z (% rel. int.). Elemental analyses were performed by Ilse Beetz Mikroanalytisches Laboratorium, Kronach, Germany, or School of Chemistry, University of Birmingham, UK. Melting points were determined with a C. Reichert melting point apparatus or a Büchi Melting Point B-545 apparatus and are uncorrected. Triethylamine, DMF and CH₂Cl₂ were distilled from CaH₂ and stored over molecular sieves (3 Å). THF and anisole and diethyl ether were distilled from Na/benzophenone. Alternatively dry THF DMF, Et₂O and CH₂Cl₂ were obtained from a solvent purification system, MB SPS-800 from MBraun. Silica gel for flash chromatography was purchased from Merck, Darmstadt, Germany (Merck No. 09385). All other reagents were commercially available and used as received. Compounds synthesized 5-Amino-4-chloro-6-(4by literature procedures: (**3**),^{3d} methoxybenzylamino)pyrimidine 4-(2-furyl)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4d]pyrimidine (6).^{3a} Activities against S. aureus,¹⁷ E. $coli^{17}$ and VERO cells¹ were determined as reported before.

Antimycobacterial data.

Minimum inhibitory concentrations (MIC) against replicating and non-replicating cultures of *Mycobacterium tuberculosis* were determined using the microplate Alamar Blue assay (MABA)¹⁴ and low oxygen recovery assay (LORA),¹⁶ respectively. The former was determined against *M. tuberculosis* H₃₇Rv ATCC 27294 (American Type Culture Collection) as well as drug-resistant *Mtb* strains following 7 days incubation with test samples. The latter was determined against low oxygen adapated *M. tuberculosis* H₃₇Rv luxAB carrying a luciferase reporter gene following 10 days incubation under low oxygen followed by 28 hours of normoxic recovery. Both assays were conducted in microplate format in 7H12 medium.^{14b} The MIC was defined as the lowest concentration effecting a reduction of 90% in fluorescence (MABA) or luminescence (LORA) relative to untreated controls.

7-Chloro-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4). A mixture of 5amino-4-chloro-6-(4-methoxybenzylamino)pyrimidine **5** (670 mg, 2.53 mmol), AcOH (50% in water, 12 mL) and NaNO₂ (192 mg, 2.78 mmol) in dichloromethane (12 mL) was stirred at ambient temperature under N₂-atm. for 30 min, diluted with dichloromethane (20 mL), washed with water (10 mL) and brine (10 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash chromatography on silica gel eluting with dichoromethane; yield 562 mg (81%), mp 110-112 °C, off-white powdery crystals. ¹H NMR (CDCl₃, 200 MHz) δ 3.75 (s, 3H, OCH₃), 5.81 (s, 2H, CH₂), 6.85 (d, *J* = 8.4 Hz, 2H, Ar), 7.42 (d, *J* = 8.4 Hz, 2H, Ar), 8.90 (s, 1H, H-5); ¹³C NMR (CDCl₃, 50 MHz) δ 51.0 (CH₂), 55.3 (OCH₃), 114.3 (CH in Ar), 125.8 (C-1 in Ar), 130.0 (CH in Ar), 134.1 (C-7a), 149.4 (C-3a / C-7), 154.0 (C-3a / C-7), 155.3 (C-5), 159.9 (C-4 in Ar); MS EI *m*/*z* (rel. %) 277 / 275 (12 / 36, *M*⁺), 248 (39), 246 (92), 234 (6), 232 (18), 218 (7), 216 (22), 134 (13), 122 (9), 121 (199); HRMS Found 275.0582, calcd. for C₁₂H₁₀ClN₅O 275.0574.

7-(2-Furyl)-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5). A mixture of 7-chloro-[3-(4-methoxybenzylamino)]-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidine **4** (278 mg, 1.00 mmol), 2-furyl(tributyl)tin (0.48 mL, 1.5 mmol) and (Ph₃P)₂PdCl₂ (36 mg. 0.050 mmol) in DMF (4 mL) was stirred at 90 °C under N₂-atm. for 4 h, and evaporated *in vacuo*. KF in MeOH (sat. sol., 10 mL) was added to the residue and the mixture stirred for 18 h. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:2) followed by EtOAc-hexane (1:1) and finally pure EtOAc; yield 275 mg (90%), mp 166-168 °C, colorless powdery crystals. ¹H NMR (CDCl₃, 200 MHz) δ 3.75 (s, 3H, OCH₃), 5.81 (s, 2H, CH₂), 6.72 (dd, *J* = 3.6 and 1.8 Hz, 1H, furyl), 6.84 (d, *J* = 8.6 Hz, 2H, Ar), 7.43 (d, *J* = 8.6 Hz, 2H, Ar), 7.82 (br s, 1H, furyl), 8.11 (br d, *J* = 3.6 Hz, 1H, furyl), 9.07 (s, 1H, H-5); ¹³C NMR (CDCl₃, 50 MHz) δ 50.1 (CH₂), 55.0 (OCH₃), 113.1 (CH in furyl), 114.0 (CH in Ar), 120.3 (CH in furyl), 126.3 (C-1 in Ar), 129.7 (CH in Ar), 130.3 (C-7a), 147.2 (CH in furyl) 147.7 (C-3a / C-7 / C-2 in furyl), 148.4 (C-3a / C-7 / C-2 in furyl), 149.1 (C-3a / C-7 / C-2 in furyl), 155.9 (C-5), 159.5 (C-4 in Ar); MS EI *m*/z (rel. %) 307 (30,

M⁺), 279 (26), 278 (82), 264 (15), 250 (17), 159 (7), 146 (9), 121 (100); HRMS Found 307.1065, calcd. for C₁₆H₁₃N₅O₂ 307.1069. Anal. Found C, 62.29; H, 4.38; N, 22.47. C₁₆H₁₃N₅O₂ requires C, 62.53; H, 4.26; N, 22.79%.

4-Chloro-7-(4-methoxybenzyl)-7*H***-pyrrolo[2,3-***d***]pyrimidine (8a**). A mixture of 4-chloro-7-deazapurine **7a** (618 mg, 3.90 mmol) and K₂CO₃ (1.62 g, 11.7 mmol, oven-dried at 110 °C for 5h) in DMF (20 mL) was stirred at ambient temperature under N₂-atm, for 30 min, before 4-methoxybenzyl chloride (1.00 mL, 7.80 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 24 h and poured into water (200 mL). The aqueous phase was extracted with EtOAc (2 × 150 mL). The combined organic layers were washed with water (100 mL) and brine (100 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:4); yield 865 mg (81%), colorless wax. ¹H NMR (CDCl₃, 300 MHz) δ 3.76 (s, 3H, OCH₃), 5.37 (s, 2H, CH₂), 6.58 (d, *J* = 3.6 Hz, 1H, H-5), 6.84 (d, *J* = 8.7 Hz, 2H, Ar), 7.15-7.18 (m, 3H, Ar and H-6), 8.66 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 48.0 (CH₂), 55.3 (CH₃), 99.9 (C-5), 114.3 (CH in Ar), 117.5 (C-4a), 128.2 (C-1 in Ar), 129.0 (C-6), 129.2 (CH in Ar), 150.7 (C-2), 151.0 (C-4 / C-7a), 152.0 (C-4 / C-7a), 159.5 (C-4 in Ar); MS EI *m*/*z* (rel. %) 275 / 273 (14 / 38, *M*⁺), 154 (14), 122 (16), 121 (100), 91 (6), 90 (2), 98 (3), 78 (13), 77 (9); HRMS Found 273.0668, calcd. for C₁₄H₁₂ClN₃O 273.0669.

2,4-Dichloro-7-(4-methoxybenzyl)-7*H***-pyrrolo[2,3-***d***]pyrimidine (8b). The title compound was synthesized from 2,4-7-deazapurine 7b** (1.25 g, 6.65 mmol) following the procedure for synthesis of compound **8a**. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:9); yield 1.85g, (90%), mp 103-105 °C, colorless crystalline solid. ¹H NMR (CDCl₃, 300 MHz) δ 3.77 (s, 3H, OCH₃), 5.31 (s, 2H, CH₂), 6.56 (d, *J* = 3.6 Hz, 1H, H-5), 6.85 (d, *J* = 8.6 Hz, 2H, Ar), 7.12 (d, *J* = 3.6 Hz, 1H, H-6), 7.17 (d, *J* = 8.6 Hz, 2H, Ar); ¹³C NMR (CDCl₃, 75 MHz) δ 48.1 (CH₂), 55.3 (CH₃), 100.3 (C-5), 114.4 (CH in Ar), 116.3 (C-4a), 127.6 (C-1 in Ar), 129.4 (CH in Ar and C-6), 152.0 (2 × C, C-2 / C-4 / C-7a), 152.6 (C-2 / C-4 / C-7a), 159.6 (C-4 in

Ar); MS EI m/z (rel. %) 309 / 307 (6 / 10, M^+), 122 (9), 121 (100), 91 (3), 90 (1), 78 (7), 77 (5); HRMS Found 307.0278, calcd. for C₁₄H₁₁Cl₂N₃O 307.0279.

4-(2-Furyl)-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9a). The compound was synthesized by Stille coupling between compound **8a** (277 mg, 1.01 mmol) and 2-furyl(tributyl)tin (0.48 mL, 1.5 mmol) following the procedure for synthesis of compound **5**. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (2:3); yield 280 mg (92%), mp 130-131 °C, colorless small needles. ¹H NMR (CDCl₃, 200 MHz) δ 3.76 (s, 3H, OCH₃), 5.39 (s, 2H, CH₂), 6.61 (dd, *J* = 3.2 and 1.6 Hz, 1H, furyl), 6.83 (d, *J* = 8.6 Hz, 2H, Ar), 6.99 (d, *J* = 3.6 Hz, 1H, H-5), 7.14-7.19 (m, 3H, Ar and H-6), 7.38 (br d, *J* = 3.2 Hz, 1H, furyl), 7.68 (br s, 1H, furyl), 8.87 (s, 1H, H-2); ¹³C NMR (CDCl₃, 50 MHz) δ 47.3 (CH₂), 55.2 (CH₃), 101.1 (C-5), 112.1 (CH in furyl), 112.6 (CH in furyl), 112.8 (C-4a), 114.1 (CH in Ar), 128.5 (C-6), 128.7 (C-1 in Ar), 128.9 (CH in Ar), 144.8 (CH in furyl), 147.1 (C in furyl), 151.3 (C-2), 151.8 (C-4 / C-7a), 153.2 (C-4 / C-7a), 159.0 (C-4 in Ar); MS EI *m*/*z* (rel. %) 305 (59, *M*⁺), 290 (3), 198 (2), 185 (7), 184 (4), 157 (4), 156 (3), 153 (2), 129 (4), 122 (14), 121 (100); HRMS Found 305.1160, calcd. for C₁₈H₁₅N₃O₂ 305.1164; Anal. Found C, 70.53, H, 5.29; N, 13.48. C₁₈H₁₅N₃O₂ requires C, 70.81; H, 4.95; N, 13.76%.

7-(4-Methoxybenzyl)-4-(2-thienyl)-7*H***-pyrrolo[2,3-***d***]pyrimidine (9b). The compound was synthesized by Stille coupling between compound 8a** (740 mg, 2.70 mmol) and 2-thienyl(tributyl)tin (1.2 mL, 3.5 mmol) following the procedure for synthesis of compound **5**. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:3); yield 850 mg (96 %), mp 109-110 °C, colorless crystals. ¹H NMR (CDCl₃, 500 MHz) δ 3.77 (s, 3H, OCH₃), 5.40 (s, 2H, CH₂), 6.84 (d, *J* = 8.7 Hz, 2H, Ar), 6.87 (d, *J* = 3.5 Hz, 1H, H-5), 7.19 (d, *J* = 8.7 Hz, 2H, Ar), 7.21 (m, 2H, H-6 and 1H in thienyl), 7.55 (d, *J* = 4.9 Hz, 1H, thienyl), 8.02 (br s, 1H, thienyl), 8.88 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 47.5 (CH₂), 55.3 (CH₃), 100.4 (C-5), 113.3 (C-4a), 114.2 (CH in Ar), 128.3-129.5 (3 × CH in thienyl, C-6 and C-1 in Ar), 129.1(CH in Ar), 142.8 (C-2 in thienyl), 151.0 (C-2), 151.2 (C-4 / C-7a), 151.8 (C-4 / C-7a), 159.4 (C-4 in Ar);

MS EI *m*/*z* (rel. %) 321 (39, *M*⁺), 306 (1), 214 (1), 200 (1), 122 (9), 121 (100), 78 (7), 77 (6); HRMS Found 321.0940, calcd. for C₁₈H₁₅N₃OS 321.0936. Anal. Found C, 66.95, H, 4.98; N, 12.82. C₁₈H₁₅N₃OS requires C, 67.27; H, 4.70; N, 13.07%.

2-Chloro-4-(2-furyl)-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9c). A mixture of tris(dibenzylideneacetone)dipalladium chloroform adduct (16 mg, 0.015 mol) and tri(2furyl)phosphine (26 mg, 0.11 mmol) in DMF (2 mL) was stirred at ambient temperature under N₂atm. for 15 min, before compound 8b (155 mg, 0.500 mmol) in DMF (2 mL) and 2furyl(tributyl)tin (0.20 mL, 0.60 mmol) were added. The resulting mixture was stirred for 8 h at 50 °C and evaporated in vacuo. A sat. solution of potassium fluoride in methanol was added to the residue and the mixture was stirred overnight and evaporated *in vacuo* together with a small amount of silica gel. The residue was added on top of a chromatography column and the product was isolated by flash chromatography on silica eluting with EtOAc-isohexane (1:12) followed by EtOAc-isohexane (1:6) and EtOAc-isohexane (1:3); yield 145 mg (85%), mp 128-130 °C, colorless crystalline solid. ¹H NMR (CDCl₃, 300 MHz) δ 3.77 (s, 3H, OCH₃), 5.33 (s, 2H, CH₂), 6.60 (dd, J = 3.6 and 1.6 Hz, 1H, H-4 in furyl), 6.84 (d, J = 8.7 Hz, 2H, Ar), 6.96 (d, J = 3.6 Hz, 1H, H-5), 7.11 (d, J = 3.6 Hz, 1H, H-6), 7.18 (d, J = 8.8 Hz, 2H, Ar), 7.45 (dd, J = 3.6 and 0.5 Hz, 1H, H-3 in furyl), 7.68 (dd, J = 1.7 and 0.6 Hz, 1H, H-5 in furyl); ¹³C NMR (CDCl₃, 75 MHz) δ 47.5 (CH₂), 55.3 (CH₃), 101.9 (C-5), 111.7 (C-4a), 112.4 (C-4 in furyl), 114.3 (CH in Ar and C-3 in furyl), 128.3 (C-1 in Ar), 129.1 (C-6), 129.3 (CH in Ar), 145.6 (C-5 in furyl), 148.8 (C-2), 152.3 (C-2 in furyl), 153.5 (C-4 / C-7a), 153.4 (C-4 / C-7a), 159.4 (C-4 in Ar); MS EI m/z (rel. %) 341 / 339 (7 / 21, M⁺), 218 (1), 122 (9), 121 (100), 91 (3), 89 (1), 78 (6), 77 (6); HRMS Found 339.0777, calcd. for C₁₈H₁₄ClN₃O₂ 339.0775. Anal. Found C, 63.76, H, 4.38; N, 12.11. C₁₈H₁₄ClN₃O₂ requires C, 63.63; H, 4.15; N, 12.37%.

2-Chloro-7-(4-methoxybenzyl)-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine (9d). The compound was synthesized by Stille coupling between compound **8b** (800 mg, 2.60 mmol) and 2-thienyl(tributyl)tin (0.10 mL, 3.1 mmol) and PdCl₂(PPh₃)₂ (5.5 mg, 0.078 mmol) as catalyst,

otherwise following the procedure for synthesis of compound **9c**. The product was isolated by flash chromatography on silica eluting with EtOAc-isohexane (1:6) followed by EtOAc-isohexane (1:3); yellow crystals, yield 550 mg (60%), mp 124-126 °C, colorless crystalline solid. ¹H NMR (CDCl₃, 300 MHz) δ 3.77 (s, 3H, OCH₃), 5.34 (s, 2H, CH₂), 6.82-6.86 (m, 3H, Ar and H-5), 7.13 (d, *J* = 3.7 Hz, 1H, H-6), 7.17-7.21 (m, 3H, Ar and 1H in thienyl), 7.57 (dd, *J* = 5.0 and 1.0 Hz, 1H, thienyl), 7.98 (dd, *J* = 3.6 and 1.0 Hz, 1H, thienyl); ¹³C NMR (CDCl₃, 75 MHz) δ 47.6 (CH₂), 55.3 (CH₃), 100.8 (C-5), 112.2 (C-4a), 114.3 (CH in Ar), 128.2 (CH in thienyl / C-1 in Ar), 128.3 (CH in thienyl / C-1 in Ar), 129.2 (C-6 / CH in thienyl), 129.4 (CH in Ar), 129.7 (C-6 / CH in thienyl), 130.4 (CH in thienyl), 141.4 (C-2 in thienyl), 152.9 (C-2 / C-4 / C-7a), 153.3 (C-2 / C-4 / C-7a), 153.4 (C-2 / C-4 / C-7a), 159.5 (C-4 in Ar); MS EI *m*/z (rel. %) 357 / 355 (7 / 19, *M*⁺), 307 (2), 121 (100), 91 (5), 78 (6), 77 (6); HRMS Found 355.0551, calcd. for C₁₈H₁₄ClN₃OS 355.0546. Anal. Found C, 60.53, H, 4.31; N, 11.64. C₁₈H₁₄ClN₃OS requires C, 60.76; H, 3.97; N, 11.81%.

4-(2-Furyl)-2-methoxy-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-*d*]**pyrimidine** (**9e**). A solution of **9c** (150 mg, 0.440 mmol) in a freshly prepared solution of sodium methoxide in methanol (ca. 1.5 M, 15 mL) was heated at reflux under N₂-atm. for 24 h. The reaction mixture was cooled to ambient temperature and quenched with sat. aq. NH₄Cl (30 mL). The resulting mixture was evaporated *in vacuo*, the suspension obtained was dissolved in EtOAc (30 mL) and washed with sat. aq. NH₄Cl (20 mL). The aqueous phase was extracted with EtOAc (3×20 mL). The combined organic phase was dried (MgSO₄) and concentrated *in vacuo*. The product was purified by flash chromatography eluting with EtOAc (1:4); yield 125 mg (84%), mp 92-94 °C, off-white crystalline solid. ¹H NMR (Me₂CO-*d*₆, 300 MHz) δ 3.75 (s, 3H, OCH₃), 4.02 (s, 3H, OCH₃), 5.34 (s, 2H, CH₂), 6.69 (dd, *J* = 3.5 and 1.76 Hz, 1H, H-4 in furyl), 6.87 (d, *J* = 8.7 Hz, 2H, Ar), 6.92 (d, *J* = 3.6 Hz, H-5), 7.30-7.34 (m, 3H, H-6 and 2H in Ar), 7.39 (dd, *J* = 3.5 and 1.6 Hz, 1H, H-3 in furyl), 7.87 (dd, *J* = 1.7 and 0.74 Hz, H-5 in furyl); ¹³C NMR (CDCl₃, 75 MHz) δ 47.7 (CH₂), 54.6 (CH₃), 55.5 (CH₃), 101.7 (C-5), 109.5 (C-4a), 113.0 (C-4 in furyl), 113.5 (C-3 in furyl), 114.8 (CH in Ar), 128.7 (C-6), 130.1 (C-H in Ar), 130.6 (C-1 in Ar), 146.3 (C-5 in furyl), 149.0 (C-7a), 154.5 (C-2 in furyl), 155.2 (C-4),

160.3 (C-4 in Ar), 162.9 (C-2); MS EI m/z (rel. %) 335 (56, M^+), 299 (6), 122 (8), 121 (100); HRMS Found 335.1269, cacld. for C₁₉H₁₅N₃O₃ 335.1270; Anal. Found C, 67.85, H, 5.00. C₁₉H₁₅N₃O₃ requires C, 68.05; H, 5.11%.

4-Chloro-7-bromo-5*H***-pyrrolo[3,2-***d***]pyrimidine (11).¹⁸** *N***-Bromosuccinimide (0.30 g, 1.7 mmol) was added in small portions to a well stirred solution of 10** (0.20 g, 1.3 mmol) in THF (10 mL) under N₂-atm., the resulting reaction mixture was stirred at ambient temperature for 2 h. A small amount of silica gel was added and the mixture was evaporated. The residue was added on top of a silica gel flash chromatography column, and the product was isolated after elution with CH₂Cl₂ followed by 5% MeOH in CH₂Cl₂; yield 190 mg (63%), mp 230-232 °C, colorless crystalline solid. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.23 (s, 1H, H-6), 8.71 (s, 1H, H-2), 12.9 (s, 1H, NH); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 89.7 (C-7), 123.9 (C-4a), 113.9 (C-6), 142.5 (C-4), 147.5 (C-7a), 149.9 (C-2); MS EI *m*/*z* (rel. %) 233 / 231 (100 / 76, *M*⁺), 198 (50), 196 (50), 117 (24); HRMS Found 230.9199, calcd. for C₆H₃BrClN₃ 230.9199. Anal. Found C, 31.21, H, 1.20; N, 17.93. C₆H₃BrClN₃ requires C, 31.00; H, 1.30; N, 18.08%.

4-Chloro-5-methyl-5*H***-pyrrolo[3,2-d]pyrimidine (12).** NaH (ca. 60% in oil, 260 mg, ca. 6.5 mmol) was added in small portions to a stirring mixture of 4-chloro-5*H*-pyrrolo[3,2-*d*]pyrimidine **10** (500 mg, 3.25 mmol) in dry DMF (10 mL) at 0 °C under N₂-atm. The resulting mixture was stirred for 1 h at 0 °C before iodomethane (0.46 mL, 3.5 mmol) was added drop wise. The reaction mixture was allowed to gradually reach ambient temperature over 2 h and again cooled to 0 °C. Acetic acid (1 mL) was added and the resulting suspension was stirred for 15 min, before the solvents were evaporated *in vacuo*. The residue was dissolved in EtOAc (50 mL) and washed with sat. aq. NaHCO₃ (25 mL) and water (25 mL). The aq. phases were extracted with EtOAc (25 mL) and the combined EtOAc extracts were dried (MgSO₄) and evaporated *in vacuo*. The product was used without further purification; yield 508 mg (93%), off-white solid. ¹H NMR (CD₃COD, 200 MHz) δ 4.17 (s, 3H, CH₃), 6.66 (d, *J* = 3.2 Hz, 1H, H-7), 7.78 (d, *J* = 3.2 Hz, 1H, H-6), 8.54 (s, 1H, H-2); MS EI *m/z* (rel. %) 169 / 167 (28/83, *M*⁺), 132 (100). Spectral data are in good agreement

with those reported before.¹⁹

7-Bromo-4-chloro-5-methyl-5*H*-pyrrolo[3,2-d]pyrimidine (13a).

Method A: NaH (27 mg, ca. 0.68 mmol, ca. 60% in oil,) was added in small portions to a well stirred solution of **11** (80 mg, 0.34 mmol) in dry DMF (2 mL) at 0 °C under N₂-atm. The reaction mixture was stirred for 1 h at 0 °C before iodomethane (0.021 mL, 0.34 mmol) was added dropwise. The reaction mixture was allowed to gradually reach ambient temperature over 1.5 h and subsequently cooled to 0 °C. Glacial acetic acid (0.1 mL) was added and resulting suspension was stirred for 10 min, before the solvents were evaporated *in vacuo*. The residue was dissolved in EtOAc (40 mL), washed with sat. aq. NaHCO₃ (40 mL) and brine (30 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash chromatography on silica gel eluting with CH₂Cl₂ followed by MeOH-CH₂Cl₂ (1:199); yield 74 mg (88%), mp 200-201 °C, colorless crystals. ¹H NMR (CDCl₃, 200 MHz) δ 4.15 (s, 3H, CH₃), 7.45 (s, 1H, H-6), 8.74 (s, 1H, H-2); ¹³C NMR (CDCl₃, 175 MHz) δ 36.5 (CH₃), 87.8 (C-7), 123.5 (C-4a / C-7a), 138.3 (C-6), 142.1 (C-4a / C-7a), 148.1 (C-4), 149.6 (C-2); MS EI *m*/*z* (rel. %) 249 / 247 / 245 (25 / 100 / 77, *M*⁺), 212 (49), 210 (51), 131 (22); HRMS Found 244.9359, calcd. for C₇H₃BrClN₃ 244.9355. Anal. Found C, 34.10, H, 1.99, N, 17.11. C₇H₃BrClN₃ requires C, 34.11, H, 2.04, N, 17.05%.

Method B: NBS (436 mg, 2.45 mmol) was added in small portions to a stirring mixture of 4-chloro-5-methyl-5*H*-pyrrolo[3,2-d]pyrimidine **12** (410 mg, 2.45 mmol) in dry dichloromethane (10 mL) at ambient temperature under N₂-atm. The resulting mixture was stirred for 2 h, diluted with dichloromethane (10 mL) and washed with water (2 × 10 mL) and brine (10 mL), dried MgSO₄) and evaporated. The product was purified by flash chromatography on silica gel eluting with MeOH-CH₂Cl₂ (1:99); yield 460 mg (76%).

7-Bromo-4-chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidine (13b). NaH (51 mg, ca. 1.3 mmol, ca. 60% in oil) was added to a solution of **11** (250 mg, 1.07 mmol) in DMF (4 mL) at 0 $^{\circ}$ C. The reaction mixture was stirred at this temperature under N₂-atm. for 1h, before (triisopropylsilyloxy)methyl chloride (0.30 mL, 1.3 mmol) was added dropwise. The reaction

mixture was allowed to reach ambient temperature over 2 h before it was cooled to 0 °C and few drops of water were added. The solvent was evaporated *in vacuo*, the residue was suspended in water (40 mL) and was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (100 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 380 mg (84%), mp 164-166 °C, colorless crystals. ¹H NMR (CDCl₃, 300 MHz) δ 1.02 (d, *J* = 6.3 Hz, 18H, 6 × CH₃), 1.11-1.18 (m, 3H, 3 × CH in *i*-Pr), 6.00 (s, 2H, CH₂), 7.68 (s, 1H, H-6), 8.79 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 11.9 (3 × CH in *i*-Pr), 17.8 (6 × CH₃), 72.3 (CH₂), 91.7 (C-7), 123.4 (C-4a), 134.6 (C-6), 142.9 (C-7a), 149.8 (C-4), 150.7 (C-2); MS ESI 422 / 420 / 418 [*M*+*H*]; HRMS Found 418.0722, calcd. for C₁₆H₂₅BrClN₃OSi+H 418.0712. Anal. Found C, 45.95, H, 6.17; N, 9.86. C₁₆H₂₅BrClN₃OSi requires C, 45.88; H, 6.02; N, 10.03%.

4-Chloro-5-methyl-5H-pyrrolo[**3**,**2**-*d*]**pyrimidine-7-carbaldehyde** (**14a**). To a suspension of compound **13a** (0.175 g, 0.700 mmol) in dry diethyl ether (8 mL) and anisole (3 mL) was added *n*-BuLi (0.63 mL, 0.91 mmol, 1.44 M sol.) at -78 °C under N₂-atm. The reaction mixture was stirred at -78 °C for 40 min, before DMF (0.27 mL, 3.5 mmol) was added drop wise. The reaction mixture was stirred at -78 °C for an additional 1 h, was quenched by the addition of of water (2 mL) and diluted with EtOAc (20 mL). The mixture was washed with water (20 mL) and the aqueous phase was extracted with EtOAc (2×15 mL). The combined organic extracts were dried (MgSO₄) and evaporated *in vacuo* and the product was isolated by flash chromatography eluting with CH₂Cl₂ followed by MeOH-CH₂Cl₂ (1:99); yield 115 mg (84%), mp 212-213 °C, off-white crystals. ¹H NMR (Me₂CO-*d*₆, 300 MHz) δ 4.31 (s, 3H, CH₃), 8.46 (s, 1H, H-6), 8.76 (s, 1H, H-2), 10.26 (s, 1H, CHO); ¹³C NMR (Me₂CO-*d*₆, 75 MHz) δ 37.9 (CH₃), 116.9 (C-7), 142.7 (C-6), 144.2 (C-4), 151.5 (C-7a), 152.3 (C-2), 183.4 (CHO), C-4a was hidden; MS EI *m*/*z* (rel. %) 197 / 195 (4 / 13 *M*⁺), 169 (32), 167 (100), 166 (39), 158 (8); HRMS Found 195.0194, cacld. for C₈H₆CIN₃O 195.0199. Anal. Found C, 49.20; H, 2.95; N, 21.46. C₈H₆CIN₃O requires C, 49.12; H, 3.09; N, 21.48%. Compound

14a was also synthesized from the iodide **13c** (130 mg, 0.44 mmol) otherwise following the same procedure; yield 59 mg (69%).

4-Chloro-5-[(triisopropylsilyloxy)methyl]-5*H***-pyrrolo[3,2-d]pyrimidine-7-carbaldehyde (14b). The product was synthesized from compound 13b** (240 mg, 0.570 mmol) as described for the synthesis of compound **14a** above and the product was isolated by flash chromatography eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 180 mg, (86%), mp 140-141 °C, colorless crystals. ¹H NMR (Me₂CO-*d*₆, 300 MHz) δ 1.07 (d, *J* = 7.0 Hz, 18H, 6 × CH₃), 1.19-1.26 (m, 3H, 3 × CH in *i*-Pr), 6.27 (s, 2H, CH₂), 8.70 (s, 1H, H-6), 8.81 (s, 1H, H-2), 10.31 (s, 1H, CHO); ¹³C NMR (Me₂CO-*d*₆, 75 MHz) δ 12.6 (3 × CH in *i*-Pr), 18.1 (6 × CH₃), 74.0 (CH₂), 117.7 (C-7), 125.1 (C-4a), 140.2 (C-6), 144.2 (C-4), 152.1 (C-7a), 152.8 (C-2), 183.8 (CHO); MS ESI 370 / 368 [*M*+*H*]; HRMS Found 368.1568, calcd. for C₁₇H₂₆ClN₃O₂Si+H 368.1556. Anal. Found C, 55.61, H, 7.16; N, 11.21. C₁₇H₂₆ClN₃O₂Si requires C, 55.49; H, 7.12; N, 11.42%.

(4-Chloro-5-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl)(4-methoxyphenyl)methanome (15a). LiCl (224 mg, 5.30 mmol) was dried under high vacuum for 1 h and then at 110 °C for 30 min. The flask fitted with air condenser was cooled under nitrogen and magnesium turnings (128 mg, 5.30 mmol) were introduced. A crystal of iodine and THF (7.5 mL) was added and the reaction mixture stirred vigorously. 4-Bromoanisol (0.67 mL, 5.3 mmol) was added slowly over a period of 10 min. The resulting reaction mixture was stirred at ambient temperature until the disappearance of magnesium (ca. 1 h). The resulting Grignard reagent was titrated against cyclohexanol using 1,10phenanthroline as indicator. To a solution of compound **14a** (170 mg, 0.870 mmol) was added the 4-methoxyphenylmagnesium bromide-LiCl solution described above (2.2 mL, 1.0 mmol, 0.47 M in THF) at 0 °C under N₂-atm. The reaction mixture was stirred at 0 °C for 20 min, before benzaldehyde (0.13 mL, 1.3 mmol) was added. The resulting mixture was stirred at ambient temperature under N₂-atm. for 40 h, a small amount of silica gel was added and the mixture evaporated. The residue was added on to of a flash chromatography column and the product eluted with a MeOH-CH₂Cl₂ mixture gradually increasing the amount of MeOH from 0.5% to 1%; yield 198 mg (74%), mp 199-200 °C, colorless crystals. ¹H NMR (CDCl₃, 300 MHz) δ 3.84 (s, 3H, OCH₃), 4.19 (s, 3H, NCH₃), 6.91 (d J = 8.8 Hz, 2H, Ar), 7.90 (d J = 8.8 Hz, 2H, Ar), 7.96 (s, 1H, H-6), 8.75 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 37.5 (NCH₃), 55.4 (OCH₃), 133.5 (CH in Ar), 116.4 (C-7), 124.9 (C-4a), 131.3 (C-1 in Ar), 132.2 (CH in Ar), 142.5 (C-6), 143.5 (C-4), 149.4 (C-7a), 151.4 (C-2), 163.4 (C-4 in Ar), 187.3 (CO); MS EI *m*/*z* (rel. %) 303 / 301 (29 / 86 M^+), 274 (37), 272 (100), 194 (36), 135 (21); HRMS Found 301.0617, cacld. for C₁₅H₁₂ClN₃O₂ 301.0618.

{4-Chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl}(4-

methoxyphenyl)methanone (**15b**). The compound was synthesized from **14b** (260 mg, 0.700 mmol) following the procedure for the synthesis of **15a** above. The product was isolated by flash chromatography eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 214 mg (64%), mp 135-138 °C, off-white crystals. ¹H NMR (CDCl₃, 300 MHz) δ 1.05 (d, J = 6.5 Hz 18H, 6 × CH₃), 1.13-1.20 (m, 3H, 3 × CH in *i*-Pr), 3.89 (s, 3H, OCH₃), 6.08 (s, 2H, CH₂), 6.95 (d J = 8.9 Hz, 2H, Ar), 7.95 (d J = 8.9 Hz, 2H, Ar), 8.19 (s, 1H, H-6), 8.83 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 12.5 (3 × CH in *i*-Pr), 17.8 (6 × CH₃), 55.5 (OCH₃), 72.9 (CH₂), 113.6 (CH in Ar), 117.2 (C-7), 124.0 (C-4a), 131.1 (C-1 in Ar), 132.3 (CH in Ar), 140.3 (C-6), 143.3 (C-4), 150.3 (C-7a), 151.7 (C-2), 163.5 (C-4 in Ar), 187.4 (CO); MS EI *m*/*z* (rel. %) 473 (7, *M*⁺), 432 (41), 430 (100), 402 (21), 400 (54), 137 (21), 135 (26); HRMS Found 473.1901, cacld. for C₂₄H₃₂ClN₃O₃Si 473.1901. Anal. Found C, 60.69, H, 6.80; N, 8.60. C₂₄H₃₂ClN₃O₃Si requires C, 60.80; H, 6.80; N, 8.86%.

[4-(2-Furyl)-5-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl](4-methoxyphenyl)methanone (16a). The compound was synthesized by Stille coupling between compound 15a (90 mg, 0.29 mmol) and 2-furyl(tributyl)tin (0.110 mL, 0.350 mmol) following the procedure for synthesis of compound 5. The product was purified by flash chromatography on silica gel eluting with CH₂Cl₂, MeOH-CH₂Cl₂ (1:199), and finally MeOH-CH₂Cl₂ (1:99); yield 70 mg (72%), mp 252-254 °C, yellow crystals. ¹H NMR (CDCl₃, 300 MHz) δ 3.84 (s, 3H, OCH₃), 4.01 (s, 3H, NCH₃), 6.64 (dd, *J* = 3.5

and 1.8 Hz 1H, H-4 in furyl), 6.19 (d, J = 8.8 Hz, 2H, Ar), 7.28 (dd, J = 3.5 and 0.8 Hz, 1H, H-3 in furyl), 7.67 (br s, 1H, H-5 in furyl), 7.92 (d, J = 8.8 Hz, 2H, Ar), 7.95 (s, 1H, H-6), 9.00 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 38.9 (NCH₃), 55.4 (OCH₃), 112.6 (C-4 in furyl), 113.4 (CH in Ar), 114.3 (C-3 in furyl), 116.0 (C-7), 124.4 (C-4a), 131.4 (C-1 in Ar), 132.1 (CH in Ar), 140.6 (C-4), 143.3 (C-6), 144.7 (C-5 in furyl), 150.3 (C-7a), 150.5 (C-2 in furyl), 151.6 (C-2), 163.1 (C-4 in Ar), 187.7 (CO); MS EI m/z (rel. %) 333 (100 M^+), 332 (60), 305 (45), 304 (85), 276 (18); HRMS Found 333.1108, cacld. for C₁₉H₁₅N₃O₃ 333.1113. Anal. Found C, 66.70; H, 4.36; N, 12.21. C₁₉H₁₅N₃O requires C, 68.46; H 4.54; N 12.61%.

{4-(2-furyl)-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl}(4-

methoxyphenyl)methanone (**16b**). A mixture of compound **15b** (645 mg, 1.40 mmol), 2furyl(tributyl)tin (0.52 mL, 1.6 mmol) and (Ph₃P)₂PdCl₂ (48 mg, 0.070 mmol) in DMF (4 mL) was stirred at 90 °C under N₂-atm for 18 h, and evaporated *in vacuo*. The residue was dissolved in MeCN (40 mL) and was washed with hexane (5 × 50 mL). Hexane (50 mL) was added to the MeCN layer and resulting mixture was stirred at ambient temperature for 1h, the layers were separated and the MeCN layer was evaporated *in vacuo*. The product was isolated by flash chromatography eluting with EtOAc-hexane (1:3); yield 450 mg (65%), mp 108-110 °C, off-white crystalline solid. ¹H NMR (Me₂CO-*d*₆, 500 MHz) δ 0.93 (d, *J* = 7.2 Hz 18H, 6 × CH₃), 1.04-1.08 (m, 3H, 3 × CH in *i*-Pr), 3.91 (s, 3H, OCH₃), 6.28 (s, 2H, CH₂), 6.78 (dd, *J* = 3.5 and 1.8 Hz 1H, H-4 in furyl), 7.04 (d *J* = 8.9 Hz, 2H, Ar), 7.38 (dd, *J* = 3.5 and 0.9 Hz, 1H, H-3 in furyl), 7.95 (m, 3H, 2H in Ar and H-5 in furyl), 8.54 (s, 1H, H-6), 8.89 (s, 1H, H-2); ¹³C NMR (Me₂CO-*d*₆, 125 MHz) δ 12.5 (3 × CH in *i*-Pr), 18.0 (6 × CH₃), 55.9 (OCH₃), 75.1 (CH₂), 113.2 (C-4 in furyl), 114.1 (CH in Ar), 114.4 (C-3 in furyl), 117.5 (C-7), 123.5 (C-4a), 132.6 (C-1 in Ar), 132.9 (CH in Ar), 141.8 (C-4), 142.6 (C-6), 146.2 (C-5 in furyl), 152.0 (C-7a), 152.2 (C-2 and C-2 in furyl), 164.2 (C-4 in Ar), 187.8 (CO); MS ESI 506 [*M*+*H*]; HRMS Found 506.2458, calcd. for C₂₈H₃₅N₃O₄Si+H 506.2470.

[4-(2-Furyl)-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl](4-methoxyphenyl)methanone (16c). A solution of compound 16b (225 mg, 0.440 mmol) in a saturated solution of KF in MeOH was stirred at

ambient temperature for 12 h before few drops of methanolic ammonia were added and resulting mixture was stirred for 1 h at ambient temperature. The product was isolated by flash chromatography eluting with EtOAc-hexane (1:1) followed by pure EtOAc; yield 120 mg (86%), mp 230-233 °C (dec.), pale yellow crystalline solid. ¹H NMR (DMSO- d_6 , 300 MHz) δ 3.85 (s, 3H, OCH₃), 6.84 (dd, *J* = 3.5 and 1.7 Hz 1H, H-4 in furyl), 7.06 (d, *J* = 8.8 Hz, 2H, Ar), 7.52 (d, *J* = 3.5, 1H, H-3 in furyl), 7.91 (d, *J* = 8.8 Hz, 2H, Ar), 8.09 (br s, 1H, H-5 in furyl), 8.33 (s, 1H, H-6), 8.86 (s, 1H, H-2); ¹³C NMR (DMSO- d_6 , 75 MHz) δ 55.5 (OCH₃), 112.8 (CH in furyl), 113.1 (CH in furyl), 113.5 (CH in Ar), 115.7 (C-7), 121.1 (C-4a), 131.4 (C-1 in Ar), 131.9 (CH in Ar), 139.2 (C-4), 139.4 (C-6), 146.4 (C-5 in furyl), 148.6 (C-7a), 150.6 (C-2 in furyl), 151.4 (C-2), 162.7 (C-4 in Ar), 187.4 (CO); MS EI *m*/*z* (rel. %) 319 (100 *M*⁺), 290 (70), 261 (17), 160 (9); HRMS Found 319.0957, calcd. for C₁₈H₁₃N₃O₃ 319.0957. Anal. Found C, 67.55, H, 4.00; N, 12.92. C₁₈H₁₃N₃O₃ requires C, 67.71; H, 4.10; N, 13.16%.

4-(2-Furyl)-7-(4-methoxybenzyl)-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (17). A suspension of **16a** (95 mg, 0.29 mmol) in ethylene glycol (3.0 mL) and hydrazine hydrate (0.28 mL, 5.7 mmol) was heated until a clear solution was obtained (ca. 10 min, ca. 70 °C) before crushed NaOH (228 mg, 5.70 mmol) was introduced. The resulting mixture was heated at 120 °C for 18 h before the reaction mixture was cooled to 0 °C and neutralized by dropwise addition of 10% aq. HCl with stirring. After complete neutralization, water (20 mL) was added and resulting mixture was extracted with EtOAc (5 × 20 mL). The combined organic phases were washed with water (50 mL) followed by brine (50 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash chromatography on silica gel eluting with CH₂Cl₂, followed by MeOH-CH₂Cl₂ (1:199) and finally MeOH-CH₂Cl₂ (7:193); yield 65 mg, (71%), mp 114-115 °C, yellow crystalline solid. ¹H NMR (CDCl₃, 200 MHz) δ 3.77 (s, 3H, OCH₃), 3.90 (s, 3H, NCH₃), 4.12 (s, 2H, CH₂), 6.65 (dd, *J* = 3.5 and 1.8 Hz 1H, H-4 in furyl), 6.83 (d, *J* = 8.7 Hz, 2H, Ar), 7.06 (s, 1H, H-6), 7.24 (d, *J* = 8.7 Hz, 2H, Ar), 7.32 (br d, *J* = 3.5 Hz, 1H, H-3 in furyl), 7.66 (dd, *J* = 1.8 and 0.8 Hz, 1H, H-5 in furyl), 8.95 (s, 1H, H-2); ¹³C NMR (CDCl₃, 75 MHz) δ 29.2 (CH₂), 38.2 (NCH₃), 55.7 (OCH₃),

112.9 (C-4 in furyl), 114.1 (C-3 in furyl), 114.4 (CH in Ar), 116.5 (C-7a), 124.6 (C-4a), 130.4 (CH in Ar), 133.4 (C-1 in Ar), 137.3 (C-6), 139.7 (C-4), 144.8 (C-5 in furyl), 149.6 (C-2), 151.4 (C-2 in furyl), 158.4 (C-4 in Ar), the signal from C-7 was hidden. MS EI m/z (rel. %) 319 (100, M^+), 318 (28), 304 (88), 288 (5), 160 (8); HRMS Found 319.1325, cacld. for C₁₉H₁₅N₃O₃ 319.1321; Anal. Found C, 71.18, H, 5.56; N, 12.69. C₁₉H₁₇N₃O₂ requires C, 71.46; H, 5.37; N, 13.16%.

Acknowledgements

The initial screening of antimycobacterial activity was performed by the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) through a research and development contract with the US National Institute of Allergy and Infectious Diseases. The Norwegian Research Council is gratefully acknowledged for a grant to ADK (KOSK II, project number 177368) as well as for partial financing of the Bruker Avance instruments used in this study.

References

- (a) Bakkestuen, A. K.; Gundersen, L.-L.; Langli, G.; Liu, F.; Nolsøe, J. M. J. Bioorg. Med. Chem. Lett. 2000, 10, 1207; (b) Gundersen, L.-L.; Nissen-Meyer, J.; Spilsberg, B. J. Med. Chem. 2002, 45, 1383; (c) Andresen, G.; Gundersen, L.-L.; Nissen-Meyer, J.; Rise, F.; Spilsberg, B. Bioorg. Med. Chem. Lett. 2002, 12, 567; (d) Bakkestuen, A. K.; Gundersen, L.-L; Utenova, B. T. J. Med. Chem. 2005, 48, 2710; (e) Brændvang, M.; Gundersen, L.-L. Bioorg. Med. Chem. 2005, 13, 6360; (f) Brændvang, M.; Gundersen, L.-L. Bioorg. Med. Chem. 2007, 15, 7144-7165; (g) Brændvang, M.; Bakken, V.; Gundersen, L.-L. Bioorg. Med. Chem. 2009, 17, 6512.
- 2 See for instance: (a) Global Alliance for TB Drug Development, *The need for new TB drugs* (2005; www.tballiance.org) (b) Bhowruth, V.; Dover, L. G.; Besra, G. S. *Prog. Med. Chem.* 2007, 45, 169.
- 3 (a) Brændvang, M.; Gundersen, L.-L. *Tetrahedron Lett.* **2007**, *48*, 3057; (b) Brændvang, M.; Charnock, C.; Gundersen, L.-L. *Bioorg. Med. Chem. Lett.* **2009**, 19, 3297; (c) Miranda, P. O.;

Gundersen, L.-L. Arch. Pharm. Chem. Life Sci. 2010, 343, 40; (d) Read, M. L.; Brændvang, M.; Miranda, P. O.; Gundersen, L.-L. Bioorg. Med. Chem. 2010, 18, 3885.

- Kelley, J. L.; Davis, R. G.; McLean, E. W.; Glen, R. C.; Soroko, F. E.; Cooper, B. R. J. Med.
 Chem. 1995, 38, 3884.
- 5 Sobolov, S. B.; Sun, J.; Cooper, B. A. Tetrahedron Lett. 1998, 39, 5685.
- (a) Niwas, S.; Chand, P.; Pathak, V. P.; Montgomery, J. A. J. Med. Chem. 1994, 37, 2477; (b)
 Smalley Jr., T. L.; Peat, A. J.; Boucheron, J. A.; Dickerson, S.; Garrido, D.; Preugschat, F.;
 Schweiker, S. L.; Thomson, S. A.; Wang, T. Y. *Bioorg. Med. Chem. Lett.* 2006, 16, 2091; (c)
 Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. J. Med. Chem.
 2003, 46, 3412; (d) Semeraro, T.; Mugnaini, C.; Corelli, F. *Tetrahedron Lett.* 2008, 49, 5965.
- (a) Rose, J. D.; Secrist III, J. A.; Montgomery, J. A. Nucleosides, Nucleotides 1999, 18, 2443;
 (b) Evans, G. B.; Furneaux, R. H.; Hutchison, T. L.; Kezar, H. S.; Morris, P. E.; Schramm, V. L.; Tyler, P. C. J. Org. Chem. 2001, 66, 5723; (c) Otmar, M.; Masojidkova, M.; Votruba, I.; Holy, A. Bioorg. Med. Chem. 2004, 12, 3189.
- 8 Shih, H.; Cottam, H. B.; Carson, D. A. Chem. Pharm. Bull. 2002, 50, 364.
- 9 (a) Evans, G. B.; Furneaux, R. H.; Hausler, H.; Larsen, J. S.; Tyler, P. C. J. Org. Chem. 2004, 69, 2217; (b) Kezar III, H. S.; Kilpatrick, J. M.; Phillips, D.; Kellogg, D.; Zhang, J.; Morris Jr., P. E. Nucleosides, Nucleotides, Nucleic Acids 2005, 24, 1817; (c) Clinch, K.; Evans, G. B.; Fleet, G. W. J.; Furneaux, R. H.; Johnson, S. W.; Lenz, D. H.; Mee, S. P. H.; Rands, P. R.; Schramm, V. L.; Taylor Ringia, E. A.; Tyler, P. C. Org. Biomol. Chem. 2006, 4, 1131.
- 10 Kloetzing, R. J.; Krasovskiy, A.; Knochel. P. Chem. Eur. J. 2007, 13, 215.
- 11 (a) Benneche, T.; Gundersen, L.-L.; Undheim, K. Acta Chem. Scand. B 1988, 42, 384; (b)
 Andresen, G.; Eriksen, A. B.; Dalhus, B.; Gundersen, L.-L.; Rise, F. J. Chem. Soc., Perkin Trans 1 2001, 1662; (c) Andresen, G.; Gundersen, L.-L.; Rise, F. ARCIVOC 2001, 35; (d)
 Zajac, M. A.; Vedejs, E. Org. Lett. 2004, 6, 237

- 12 (a) Gundersen, L.-L.; Benneche, T.; Undheim, K. Acta Chem. Scand. 1989, 43, 706; (b) Shindo,
 M.; Sugioka, T.; Umaba, Y.; Shishido, K. Tetrahedron Lett. 2004, 45, 8863.
- 13 (a) Pitsch, S.; Weiss, P. A.; Wu, X.; Ackermann, D.; Honegger, T. *Helv. Chim. Acta* 1999, 82, 1753; (b) Pitsch, S.; Weiss, P. A.; Jenny, L.; Stutz, A.; Wu, X. *Helv. Chim. Acta* 2001, 84. 3773.
- 14 (a) Collins, L. A.; Franzblau, S. G. Antimicrob. Agents Chemother. 1997, 41, 1004; (b)
 Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. Antimicrob. Agents Chemother. 2005, 49, 1447.
- 15 Stover, C. K.; Warrener, P.; VanDevandter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. *Nature* 2000, 405, 962-966.
- 16 Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Antimicrob. Agents Chemother. 2007, 51, 1380-1385.
- 17 Vik, A.; Hedner, E.; Charnock, C.; Samuelsen, Ø.; Larsson, R.; Gundersen, L.-L.; Bohlin. L. J.
 Nat. Prod. 2006, 69, 381.
- 18 Kuzmich, D.; Disalvo, D.; Razavi, H. PCT Int. Appl. WO 2008070507 2008, 273pp.
- 19 Vaisburg, A.; William, S.; Raeppel, F.; Saavedra, O. M.; Berstein, N.; Granger, M.-C.; Zhan, L. PCT Int. Appl. WO 2006010264 2006, 283 pp.

Legends to Figures and Schemes


Fig. 1. SAR summary for antimycobacterial purines **A**, structures of some of the most active purines (**1a-1f**), general structures of pyrimidine- **B** and imidazole analogs **C** and general structure of the target compounds **D** described in this study.

Fig. 2. Structure of compound 6.


Scheme 1. (a) p-MeO-C₆H₄-CH₂NH₂, Et₃N, n-BuOH, Δ ; (b) NaNO₂, AcOH, CH₂Cl₂, H₂O; (c) (2-Furyl)SnBu₃, (Ph₃P)₂PdCl₂; DMF, 90 °C.

Scheme 2. (a) p-MeO-C₆H₄-CH₂Cl, K₂CO₃, DMF; (b) R = H: (2-Furyl)SnBu₃ or (2-Thienyl)SnBu₃ (Ph₃P)₂PdCl₂, DMF, 90 °C; (c) R = Cl: (2-furyl)SnBu₃ or (2-thienyl)SnBu₃, [(2-Furyl)₃P]₄Pd or (Ph₃P)₂PdCl₂, DMF, 50 °C; (d) MeONa, MeOH, Δ .


Scheme 3. (a) NBS, THF; (b) NaH, MeI, DMF; (c) NaH, TOM-Cl, THF, 0 °C – r.t.; (d) NBS, CH₂Cl₂; (e) 1. *n*-BuLi, Et₂O, anisole, -78 °C, 2. DMF; (f) 1. *p*-MeO-C₆H₄-MgBr, LiCl, THF, 0 °C – r.t., 2. PhCHO; (g) 1. (2-Furyl)SnBu₃, (Ph₃P)₂PdCl₂, DMF, 90 °C; (h) KF, MeOH; (i) NH₂NH₂, NaOH, H₂O, HOCH₂CH₂OH, 120 °C.




(Fig 1)




(Fig 2)



(Scheme 1)



(Scheme 2)



(Scheme 3)